Spring Creek Capital’s Amedisys AMED Stock Holding History

Spring Creek Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,889	Closed	-$503K	–	65
2018 Q2	$503K	Buy	+5,889	New	+$432K	0.06%	394

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Spring Creek Capital's AMED Position: Q3 2018 in Review

Spring Creek Capital sold out of Amedisys (AMED) in Q3 2018, closing a stake of 5,889 shares — an estimated $503K sold.

Spring Creek Capital first reported a position in AMED in Q2 2018 and held it in 1 quarter. The position peaked at $503K in Q2 2018. 265 funds tracked by Wall St. Rank hold AMED as of Q3 2018.

Spring Creek Capital reported no remaining Amedisys position as of Q3 2018 after selling out during the quarter.
Spring Creek Capital sold 5,889 Amedisys shares in Q3 2018, an estimated $503K.
Spring Creek Capital first reported a position in Amedisys in Q2 2018 and held it in 1 quarter.
Spring Creek Capital's Amedisys position peaked at $503K in Q2 2018.
265 funds tracked by Wall St. Rank held Amedisys as of Q3 2018.

Based on Spring Creek Capital's 13F filing for Q3 2018, filed 13 Nov 2018.